Trial reportThe Journal of clinical psychiatry
Psychotherapy Alone and Combined With Medication as Treatments for Bipolar II Depression: A Randomized Controlled Trial.
Trial report in The Journal of clinical psychiatry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01133821 (Acute Psychotherapy for Bipolar II Depression), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Acute Psychotherapy for Bipolar II Depression
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Toward a Digital Future in Bipolar Disorder Assessment: A Systematic Review of Disruptions in the Rest-Activity Cycle as Measured by Actigraphy.Frontiers in psychiatry · 2022Pooled it
- New Developments in the Use of Atypical Antipsychotics in the Treatment of Bipolar Disorder: a Systematic Review of Recent Randomized Controlled Trials.Current psychiatry reports · 2021Pooled it
- [Relapse prevention of bipolar disorders: a cluster analytical approach in a randomized controlled psychotherapy study].Der Nervenarzt · 2025Trial
- Article
- Are People Worse Off in a Mental Health Treatment Paradigm Where Medication Is Deemphasised? A Naturalistic Noninferiority Trial of an Initiative to Improve Patient Choice.The International journal of social psychiatry · 2026Article
- Bipolar II disorder: a state-of-the-art review.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2025Article
- Genistein improves depression-like behavior in rats by regulating intestinal flora and altering glutamate gene expression.Current research in food science · 2025Article
- Bipolar II Disorder: Understudied and Underdiagnosed.Focus (American Psychiatric Publishing) · 2023Review
- Ethical and Legal Aspects of Treating Bipolar Disorder.Focus (American Psychiatric Publishing) · 2023Article
- Assessment and Management of Bipolar Disorder.Focus (American Psychiatric Publishing) · 2023Article
- A framework for precision "dosing" of mental healthcare services: algorithm development and clinical pilot.International journal of mental health systems · 2023Article
- Insomnia and circadian rhythm: a bibliometrics study and visualization analysisFrontiers in neurology · 2023Article
- Comorbidity and familial aggregation of back/neck pain in the NIMH Family Study of Affective Spectrum Disorders.Journal of psychosomatic research · 2022Article
- Is cognitive behaviour therapy applicable to individuals diagnosed with bipolar depression or suboptimal mood stabilizer treatment: a secondary analysis of a large pragmatic effectiveness trial.International journal of bipolar disorders · 2022Article
- National Institute of Mental Health Life Chart Method - Self/Prospective (NIMH-LCM-S/P™): translation and adaptation to Brazilian Portuguese.Trends in psychiatry and psychotherapy · 2022Article
- Changes in inflammation with treatment for bipolar II depression: Pilot trial data on differential effects of psychotherapy and medication.Neurology, psychiatry, and brain research · 2019Article
- Evidence-Based Psychotherapies for Bipolar Disorder.Focus (American Psychiatric Publishing) · 2019Review
- Treating Circadian Rhythm Disruption in Bipolar Disorder.Current psychiatry reports · 2019Review
- [Psychotherapy for people with bipolar disorders : An overview of evidence-based procedures and new developments].Der Nervenarzt · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveBipolar II disorder (BP-II) is associated with marked morbidity and mortality. Quetiapine, the treatment with greatest evidence for efficacy in BP-II depression, is associated with metabolic burden. Psychotherapy, a treatment with few side effects, has not been systematically evaluated in BP-II. This study compared psychotherapy plus placebo to psychotherapy plus pharmacotherapy as treatments for BP-II depression.
methodsFrom 2010 to 2015, unmedicated adults (n = 92) with DSM-IV-TR BP-II depression were randomly assigned to weekly sessions of Interpersonal and Social Rhythm Therapy (IPSRT) plus placebo or IPSRT plus quetiapine and followed for 20 weeks.
resultsFor primary outcomes, IPSRT + quetiapine yielded significantly faster improvement on 17-item Hamilton Depression Rating Scale (F₁,₁₁₅.₄ = 3.924, P = .048) and greater improvement on Young Mania Rating Scale (F₅₈.₅ = 4.242, P = .044) scores. Both groups, however, improved significantly over time with comparable response rates (≥ 50% reduction in depression scores): 67.4% (62/92) in the entire sample, with no between-group differences. Those randomly assigned to their preferred treatment were 4.5 times more likely to respond (OR = 4.48, 95% CI = 1.20-16.77, P = .026). IPSRT + quetiapine assignment was associated with significantly higher body mass index over time (F₆₇.₉₆ = 6.671, P = .012) and rates of dry mouth (79% v. 58%; χ² = 4.0, P = .046) and a trend toward more complaints of oversedation (100% vs 92%; χ² = 3.4, P = .063).
conclusionsIPSRT plus quetiapine resulted in greater symptomatic improvement but also more side effects than IPSRT alone. A subset of participants improved with IPSRT alone, although absence of an inactive comparator limits interpretation of this finding. Receipt of preferred treatment was associated with better outcomes. Harms, benefits, and preferences should be considered when recommending treatments for BP-II depression.
trial registrationClinicalTrials.gov identifier: NCT01133821.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.